One size should not fit all: advancing toward personalized glioblastoma therapy.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Discover medicine

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  PMID 26175405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MGMT methylation in glioblastoma: tale of the tail.

  2015cited by this paper
• EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

  2014cited by this paper
• Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

  2014cited by this paper
• The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

  2014cited by this paper
• Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

  2014cited by this paper
• A randomized trial of bevacizumab for newly diagnosed glioblastoma.

  2014cited by this paper
• Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

  2014cited by this paper
• Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma

  2014cited by this paper
• Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.

  2013cited by this paper
• Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013cited by this paper
• Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

  2013cited by this paper
• A systematic review of treatment guidelines for metastatic colorectal cancer

  2012cited by this paper
• Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

  2012cited by this paper
• Drug Resistance in Glioblastoma: A Mini Review

  2012cited by this paper
• Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

  2012cited by this paper
• Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

  2012cited by this paper
• Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response

  2012cited by this paper
• Cancer stem cells: impact, heterogeneity, and uncertainty.

  2012cited by this paper
• Clonal evolution in cancer

  2012cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cited by this paper
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

  2011cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

  2011cited by this paper
• Molecular signatures classify astrocytic gliomas by IDH1 mutation status

  2011cited by this paper
• Intratumoral Patterns of Genomic Imbalance in Glioblastomas

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

  2009cited by this paper
• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

  2009cited by this paper
• MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

  2009cited by this paper
• FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.

  2009cited by this paper
• Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

  2009cited by this paper
• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

  2009cited by this paper
• Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

  2007cited by this paper
• Angiogenesis in brain tumours

  2007cited by this paper
• Genetic pathways to primary and secondary glioblastoma.

  2007cited by this paper
• Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.

  2006cited by this paper
• Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

  2006cited by this paper
• MGMT gene silencing and benefit from temozolomide in glioblastoma.

  2005cited by this paper
• Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

  2005cited by this paper
• MGMT: its role in cancer aetiology and cancer therapeutics

  2004cited by this paper
• Genetic Pathways to Glioblastoma

  2004cited by this paper
• Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas.

  2003cited by this paper
• Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells.

  1999cited by this paper
• Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

  1999cited by this paper
• Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas.

  1998cited by this paper
• Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo

  1992cited by this paper

• Texture Analysis of the Apparent Diffusion Coefficient Focused on Contrast-Enhancing Lesions in Predicting Survival for Bevacizumab-Treated Patients with Recurrent Glioblastoma

  2023cites this paper
• Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments

  2021cites this paper
• C/EBPβ mediates NQO1 and GSTP1 anti-oxidative reductases expression in glioblastoma, promoting brain tumor proliferation

  2020cites this paper
• Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma

  2020cites this paper
• ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma

  2019cites this paper
• Reduction of intratumoral brain perfusion by noninvasive transcranial electrical stimulation

  2019cites this paper
• NQO1 Is Regulated by PTEN in Glioblastoma, Mediating Cell Proliferation and Oxidative Stress

  2018cites this paper
• Impact of PKCε downregulation on autophagy in glioblastoma cells

  2018cites this paper
• Male Infertility, Precision Medicine and Systems Proteomics

  2018cites this paper
• MicroRNA-675 promotes glioma cell proliferation and motility by negatively regulating retinoblastoma 1.

  2017cites this paper
• Role of Redox Status in Development of Glioblastoma

  2016cites this paper
• Personalized medicine in neuro-oncology.

  2016cites this paper
• The Long Non-coding RNA HIF1A-AS2 Facilitates the Maintenance of Mesenchymal Glioblastoma Stem-like Cells in Hypoxic Niches.

  2016cites this paper
• Glioblastoma Invoking "Killer" Rabbits of the Middle Ages.

  2016cites this paper
• Delivery And Efficacy Of CDK4/6 Inhibitors In The Treatment Of Brain Tumors

  2016cites this paper